Cardiovascular comorbidity in non-alcoholic fatty liver disease

Тимакова, А. Ю.; Скирденко, Ю П; Ливзан, М. А.; Кролевец, Т. С.; Николаев, Н. А.; Нелидова, А. В.

doi:10.31146/1682-8658-ecg-182-10-88-95

Cited by 5 publications

(4 citation statements)

References 41 publications

(68 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Исследования, проведенные на кафедре факультетской терапии и гастроэнтерологии ФГБОУ ВО в ОмГМУ показали, что гиперлептинемия и лептинорезистентность ассоциированы с более тяжелым течением НАЖБП и развитием фиброза [28] Лептин потенцирует b-окисление жирных кислот и обладает профиброгенным действием, что реализуется через увеличение образования трансформирующего фактора роста b и проколлагена I типа, увеличение пролиферации эндотелиоцитов и продукции ими активных форм кислорода. Кроме того, лептин уменьшает уровень липопротеинов высокой плотности, т. е. способствует развитию дислипидемии [29].…”

Section: лептин и адипонектинunclassified

Role of adipokines in the formation of metabolic disorders in conditions of metabolic-associated fatty liver disease (MAFLD)

Livzan,

Krolevets,

Syrovenko

2024

jour

View full text Add to dashboard Cite

The aim of this review is to summarise the current knowledge on the role of adipokines on the development and progression of MAFLD. Discussion: diagnostic criteria for metabolic-associated liver disease (MAFLD) versus non-alcoholic fatty liver disease (NAFLD) are presented. The pathogenetic aspects of metabolic disorders in MAFLD are discussed. The potential role of various adipokines such as leptin, resistin, vasfastin, ghrelin, adiponectin and others is considered. Data from our own studies and foreign studies are presented. Conclusion: given the pandemic growth of MAFLD and its association with cardiovascular risk and obesity, the question of how to properly curate patients with comorbid to reduce risks is timely and highly relevant. Adipokines contribute significantly to the pathogenesis of MAFLD. Among all, leptin and adiponectin are the most promising and well studied. That is why strategies aimed at restoring leptin and adiponectin balance may have an impact on the course of MAFLD.

show abstract

Section: лептин и адипонектинunclassified

Role of adipokines in the formation of metabolic disorders in conditions of metabolic-associated fatty liver disease (MAFLD)

Livzan,

Krolevets,

Syrovenko

2024

jour

View full text Add to dashboard Cite

show abstract

“…Исходно гиперлептинемия (референтный уровень <7,6 нг/мл) зарегистрирована у 14 из 20 пациентов, что свидетельствует о лептинорезистентности и ассоциируется с более тяжелым течением метаболически-ассоциированной жировой болезни печени (НАЖБП), свой ственной МС [12,13]. Значимого эффекта, исследуемого БАД «LINNI SLIM» в отношении уровня сывороточного лептина, как косвенного признака объема жировых накоплений, не отмечено (p=0,33).…”

Section: результаты и обсуждениеunclassified

4-week results of “Linni Slim” synbiotic in patients with metabolic syndrome

Rudoy,

Silivinchik

2024

ECG

View full text Add to dashboard Cite

The purpose of the study is to evaluate the efficacy and safety of a synbiotic in a short-term course (4 weeks), including an extract of garcinia cambogia, probiotics and prebiotics in patients with MS Materials and methods. The pilot, observational, open-label, non-randomized prospective clinical trial included 20 patients with metabolic syndrome (13 males and 7 females, Me age 42 years). A biologically active food supplement (synbiotic) “LINNI SLIM” (PharmlandBIO, Republic of Belarus) was used, including an extract of garcinia cambogia (containing 60% hydroxycitric acid, 0.03 g/g), probiotic strains of the genus Bifidobacterium (B. bifidum, B. animalis ssp lactis, B. longum ssp longum) CFU/g) - 0.066x 109 CFU/g and Lactobacillus (L. Acidophilus, L. Plantarum, L. Rhamnosus, L. Casei, L. Crispatus, L. Reuteri, L. Gasseri) - 0,134 x 109 CFU/g; prebiotics (psyllium husk, microcrystalline cellulose, linseed fiber, inulin, fenugreek). The daily dose of garcinia cambogia is 0.3 g, dietary fiber is 5.16 g. The parameters of nutritional (including bioimpedance analysis) and metabolic status, safety (hepatotoxic effects) and tolerability (gastrointestinal symptoms, 2H-breath test with lactulose and glucose) were evaluated. Results. There was a significant decrease in serum concentrations of insulin (15.2 [9.7; 23.0] Vs 10.9 [6.6; 16.4] mcU/ml; p=0.002), triglycerides (2.1 [1.4; 2.3] Vs 1.2 [1.2; 1.9] mmol/l; p=0.002), values of the HOMA-IR index (3.77 [2.54; 6.08] Vs 2.50 [1.44; 3.65]; p=0.003) without deviation of serum biomarkers of liver damage. Good tolerability and safety of “LINNI SLIM” was established: the appearance of symptoms of dyspepsia, stool disorders requiring the abolition of dietary supplements, deviations in the results of the 2H-breath test were not registered. Conclusion. A 4-week course of using the “LINNI SLIM” synbiotic at a daily dose of 10 grams has a positive effect on the metabolic status of the body (reduction of insulin, triglycerides, HOMA-IR - insulin resistance index) with satisfactory safety parameters. The effectiveness and improvement of “metabolic health” allows the use of the “LINNI SLIM” synbiotic in the initial therapy for reducing (controlling) body weight in people suffering from metabolic syndrome on the background of obesity.

show abstract

“…Адипонектин также может непосредственно ингибировать фактор некроза опухоли α (TNF-α), участвующий в пролиферации опухолевых клеток и ангиогенезе. Поскольку пациенты с НАЖБП имеют низкий уровень адипонектина в сыворотке крови, описанные выше механизмы представляют собой интересную связь между НАЖБП и развитием рака различных локализаций [48].…”

Section: обсуждение возможных механизмов канцерогенеза при нажбпunclassified

Metabolic-associated fatty liver disease (NAFLD) as a cancer risk factor

Кролевец

Livzan

2023

jour

View full text Add to dashboard Cite

The purpose of this review was to update information on the prevalence and relationship of cancer development of various localizations with non-alcoholic, metabolic-associated fatty liver disease (NAFLD/MAFLD). Discussion: The second most common cause of death among patients with NAFLD are malignant neoplasms both in the gastrointestinal tract (liver, colon, esophagus, stomach and pancreas) and in other organs (kidneys, prostate gland in men and mammary gland in women). Obesity and other metabolic disorders are associated with an increase in morbidity or mortality from various types of cancer. Due to the high prevalence of NAFLD among patients with metabolic syndrome, type 2 diabetes mellitus, an extrapolation of this development is assumed among patients with NAFLD. Metabolic disorders, imbalance of the intestinal microflora are considered as possible pathogenetic mechanisms for increasing the risk of cancer among patients suffering from NAFLD. Conclusion: in addition to the risk of developing hepatocellular carcinoma as a natural course of the disease, convincing evidence is accumulating for the role of NAFLD as an independent risk factor for the development and progression of cancer, especially in the gastrointestinal tract.

show abstract

Cardiovascular comorbidity in non-alcoholic fatty liver disease

Cited by 5 publications

References 41 publications

Role of adipokines in the formation of metabolic disorders in conditions of metabolic-associated fatty liver disease (MAFLD)

Role of adipokines in the formation of metabolic disorders in conditions of metabolic-associated fatty liver disease (MAFLD)

4-week results of “Linni Slim” synbiotic in patients with metabolic syndrome

Metabolic-associated fatty liver disease (NAFLD) as a cancer risk factor

Contact Info

Product

Resources

About